Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis

The importance of cross-protection

Filippo Ansaldi, Paola Canepa, Valentina Parodi, Sabrina Bacilieri, Andrea Orsi, Federica Compagnino, Giancarlo Icardi, Paolo Durando

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Vaccination is considered the most effective means of reducing influenza burden, providing substantial benefits in terms of reduction of morbidity, complications, hospitalizations and deaths, even if vaccines have been associated with a reduced immune response and lower effectiveness in older adults, in particular when a mismatch between the vaccine and the circulating virus strains occurred. Several strategies have been proposed to enhance vaccine protection against drifted strains, including the use of adjuvants. Among oil-emulsion adjuvants, MF-59 was approved for human use more than a decade ago and it is largely used for adjuvantation of influenza vaccine. Recent studies have demonstrated that addition of the MF-59 to subunit influenza vaccine can lead to higher haemagglutination-inhibiting seroprotection rates and to higher neutralization antibody titers against drifted strains not included in the vaccine respect to non-adjuvanted vaccine. Promising results were obtained using a new generation of oil-in-water emulsion adjuvants, named AS, offering cross-protection against heterologous challenge in ferrets.

Original languageEnglish
Pages (from-to)3345-3348
Number of pages4
JournalVaccine
Volume27
Issue number25-26
DOIs
Publication statusPublished - May 26 2009

Fingerprint

Cross Protection
Influenza Vaccines
influenza
metamorphosis
Vaccines
vaccines
Emulsions
adjuvants
Oils
emulsions
Ferrets
Subunit Vaccines
Hemagglutination
Human Influenza
Vaccination
Hospitalization
ferrets
hemagglutination
neutralization
Viruses

Keywords

  • Antigenic drift
  • Cross-protection
  • Oil-in-water adjuvants

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Ansaldi, F., Canepa, P., Parodi, V., Bacilieri, S., Orsi, A., Compagnino, F., ... Durando, P. (2009). Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection. Vaccine, 27(25-26), 3345-3348. https://doi.org/10.1016/j.vaccine.2009.01.081

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis : The importance of cross-protection. / Ansaldi, Filippo; Canepa, Paola; Parodi, Valentina; Bacilieri, Sabrina; Orsi, Andrea; Compagnino, Federica; Icardi, Giancarlo; Durando, Paolo.

In: Vaccine, Vol. 27, No. 25-26, 26.05.2009, p. 3345-3348.

Research output: Contribution to journalArticle

Ansaldi, F, Canepa, P, Parodi, V, Bacilieri, S, Orsi, A, Compagnino, F, Icardi, G & Durando, P 2009, 'Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection', Vaccine, vol. 27, no. 25-26, pp. 3345-3348. https://doi.org/10.1016/j.vaccine.2009.01.081
Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, Compagnino F et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection. Vaccine. 2009 May 26;27(25-26):3345-3348. https://doi.org/10.1016/j.vaccine.2009.01.081
Ansaldi, Filippo ; Canepa, Paola ; Parodi, Valentina ; Bacilieri, Sabrina ; Orsi, Andrea ; Compagnino, Federica ; Icardi, Giancarlo ; Durando, Paolo. / Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis : The importance of cross-protection. In: Vaccine. 2009 ; Vol. 27, No. 25-26. pp. 3345-3348.
@article{cc51330fd04545b686c74dfc6840d005,
title = "Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection",
abstract = "Vaccination is considered the most effective means of reducing influenza burden, providing substantial benefits in terms of reduction of morbidity, complications, hospitalizations and deaths, even if vaccines have been associated with a reduced immune response and lower effectiveness in older adults, in particular when a mismatch between the vaccine and the circulating virus strains occurred. Several strategies have been proposed to enhance vaccine protection against drifted strains, including the use of adjuvants. Among oil-emulsion adjuvants, MF-59 was approved for human use more than a decade ago and it is largely used for adjuvantation of influenza vaccine. Recent studies have demonstrated that addition of the MF-59 to subunit influenza vaccine can lead to higher haemagglutination-inhibiting seroprotection rates and to higher neutralization antibody titers against drifted strains not included in the vaccine respect to non-adjuvanted vaccine. Promising results were obtained using a new generation of oil-in-water emulsion adjuvants, named AS, offering cross-protection against heterologous challenge in ferrets.",
keywords = "Antigenic drift, Cross-protection, Oil-in-water adjuvants",
author = "Filippo Ansaldi and Paola Canepa and Valentina Parodi and Sabrina Bacilieri and Andrea Orsi and Federica Compagnino and Giancarlo Icardi and Paolo Durando",
year = "2009",
month = "5",
day = "26",
doi = "10.1016/j.vaccine.2009.01.081",
language = "English",
volume = "27",
pages = "3345--3348",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "25-26",

}

TY - JOUR

T1 - Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis

T2 - The importance of cross-protection

AU - Ansaldi, Filippo

AU - Canepa, Paola

AU - Parodi, Valentina

AU - Bacilieri, Sabrina

AU - Orsi, Andrea

AU - Compagnino, Federica

AU - Icardi, Giancarlo

AU - Durando, Paolo

PY - 2009/5/26

Y1 - 2009/5/26

N2 - Vaccination is considered the most effective means of reducing influenza burden, providing substantial benefits in terms of reduction of morbidity, complications, hospitalizations and deaths, even if vaccines have been associated with a reduced immune response and lower effectiveness in older adults, in particular when a mismatch between the vaccine and the circulating virus strains occurred. Several strategies have been proposed to enhance vaccine protection against drifted strains, including the use of adjuvants. Among oil-emulsion adjuvants, MF-59 was approved for human use more than a decade ago and it is largely used for adjuvantation of influenza vaccine. Recent studies have demonstrated that addition of the MF-59 to subunit influenza vaccine can lead to higher haemagglutination-inhibiting seroprotection rates and to higher neutralization antibody titers against drifted strains not included in the vaccine respect to non-adjuvanted vaccine. Promising results were obtained using a new generation of oil-in-water emulsion adjuvants, named AS, offering cross-protection against heterologous challenge in ferrets.

AB - Vaccination is considered the most effective means of reducing influenza burden, providing substantial benefits in terms of reduction of morbidity, complications, hospitalizations and deaths, even if vaccines have been associated with a reduced immune response and lower effectiveness in older adults, in particular when a mismatch between the vaccine and the circulating virus strains occurred. Several strategies have been proposed to enhance vaccine protection against drifted strains, including the use of adjuvants. Among oil-emulsion adjuvants, MF-59 was approved for human use more than a decade ago and it is largely used for adjuvantation of influenza vaccine. Recent studies have demonstrated that addition of the MF-59 to subunit influenza vaccine can lead to higher haemagglutination-inhibiting seroprotection rates and to higher neutralization antibody titers against drifted strains not included in the vaccine respect to non-adjuvanted vaccine. Promising results were obtained using a new generation of oil-in-water emulsion adjuvants, named AS, offering cross-protection against heterologous challenge in ferrets.

KW - Antigenic drift

KW - Cross-protection

KW - Oil-in-water adjuvants

UR - http://www.scopus.com/inward/record.url?scp=67349145958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349145958&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.01.081

DO - 10.1016/j.vaccine.2009.01.081

M3 - Article

VL - 27

SP - 3345

EP - 3348

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 25-26

ER -